REGULATORYTwenty-point deficit erased: Arch Manning leads Texas Longhorns past No. 1 Ohio StateSep 13, 2026
JNJApollo in talks to buy J&J's DePuy Synthes at close to $20 billionSep 13, 2026
SHOP$160 Bernstein target on Shopify lands below Street consensus as stock trades at 51x forward earningsSep 13, 2026
$BTCRevolut data breach exposes KYC and Bitcoin transaction records after fake government domain requestSep 13, 2026
ABNBOver $40 million per program, 1,234 miles: Ohio State arrives in Austin for a Texas rematch with playoff stakesSep 13, 2026
EARNINGSLululemon (LULU) cuts full-year guidance again as leggings shrink about 20% and China sentiment turnsSep 13, 2026
DEALSPlusAI targets $800 million valuation in Texas Ventures SPAC dealSep 13, 2026
IMUXImmunic board contracts to nine seats after Nash departureSep 13, 2026
REGULATORYTwenty-point deficit erased: Arch Manning leads Texas Longhorns past No. 1 Ohio StateSep 13, 2026
JNJApollo in talks to buy J&J's DePuy Synthes at close to $20 billionSep 13, 2026
SHOP$160 Bernstein target on Shopify lands below Street consensus as stock trades at 51x forward earningsSep 13, 2026
$BTCRevolut data breach exposes KYC and Bitcoin transaction records after fake government domain requestSep 13, 2026
ABNBOver $40 million per program, 1,234 miles: Ohio State arrives in Austin for a Texas rematch with playoff stakesSep 13, 2026
EARNINGSLululemon (LULU) cuts full-year guidance again as leggings shrink about 20% and China sentiment turnsSep 13, 2026
DEALSPlusAI targets $800 million valuation in Texas Ventures SPAC dealSep 13, 2026
IMUXImmunic board contracts to nine seats after Nash departureSep 13, 2026

Apollo in talks to buy J&J's DePuy Synthes at close to $20 billion

Close to $20 billion is what alternative asset manager Apollo Global Management is discussing for Johnson & Johnson's orthopedics unit, DePuy Synthes, according to people familiar with the talks who asked not to be identified. At DePuy…

By Lucia Moretti·Sep 13, 2026·2 min read·deals·JNJ

Key takeaways

  • Apollo Global Management is in talks to buy Johnson & Johnson's orthopedics unit DePuy Synthes for close to $20 billion, according to people familiar with the talks.
  • The roughly $20 billion bid implies a revenue multiple near 2.1x based on DePuy Synthes's reported $9.3 billion in 2025 sales.
  • Bloomberg Intelligence analyst Matt Henriksson estimated the business could be worth $28 billion including debt, about $8 billion above the current bid.
  • J&J announced the separation plan last October and remains on track for a mid-2027 separation of DePuy Synthes.
  • A deal at the discussed valuation would be Apollo's largest healthcare investment yet, though an agreement could take several weeks and talks could still collapse.

Close to $20 billion is what alternative asset manager Apollo Global Management is discussing for Johnson & Johnson's orthopedics unit, DePuy Synthes, according to people familiar with the talks who asked not to be identified. At DePuy Synthes's reported $9.3 billion in 2025 sales, that figure implies a revenue multiple near 2.1x. Bloomberg Intelligence analyst Matt Henriksson has estimated the business could be valued at $28 billion including debt, placing the current bid roughly $8 billion below his estimate.

Metric Value Label
DePuy Synthes 2025 revenue $9.3B Reported
Apollo bid ~$20B Reported; per people familiar
Revenue multiple on bid ~2.1x Math reconciles
BI valuation est. (incl. debt) $28B Estimated (Henriksson, Bloomberg Intelligence)

The separation

DePuy Synthes makes devices for hip and knee replacements. J&J has said the unit would be the world's largest standalone orthopedics company if separated. The conglomerate announced the separation plan last October. On J&J's July earnings call, CFO Joseph Wolk said J&J is pleased with its progress and remains on track for a mid-2027 separation, while continuing to evaluate all options that create shareholder value and position DePuy Synthes for long-term success.

A deal at the discussed valuation would be Apollo's largest healthcare investment yet. The asset is seen as stable, giving Apollo a sizable capital deployment opportunity, the people said. Several private equity firms have shown interest; Bloomberg reported in February that multiple buyout firms were considering a consortium bid. An agreement could come within several weeks, per the people familiar, though talks could still collapse, another bidder could emerge, or J&J could opt for a public spinoff instead.

J&J's shares were little changed at $265.58 Friday in New York, giving the company a market capitalization of $640 billion. Apollo shares gained 0.8% to $128.98 for a market cap of $76 billion. Both companies declined to comment.

Related reading

Share
© 2026 NewsMeter

Frequently asked

What is DePuy Synthes?

DePuy Synthes is Johnson & Johnson's orthopedics unit that makes devices for hip and knee replacements, which J&J says would be the world's largest standalone orthopedics company if separated.

How much is Apollo offering for DePuy Synthes?

Apollo is discussing a price close to $20 billion, which implies a revenue multiple near 2.1x on the unit's reported $9.3 billion in 2025 sales.

When could a deal be reached?

An agreement could come within several weeks, though talks could still collapse, another bidder could emerge, or J&J could opt for a public spinoff instead.

How does the bid compare to analyst valuations?

Bloomberg Intelligence analyst Matt Henriksson estimated the business could be valued at $28 billion including debt, placing the current bid roughly $8 billion below his estimate.

What is J&J's timeline for separating the unit?

J&J announced the separation plan last October and, per CFO Joseph Wolk on the July earnings call, remains on track for a mid-2027 separation while continuing to evaluate all options.